Valneva Awarded FDA Breakthrough Designation for Chikungunya Vaccine CandidateBreakthrough Therapy Designation, Chikungunya virus, European Medicines Agency (EMA), FDA, Mosquito-Borne Infections, Priority Medicines (PRIME) Designation, R&DValneva SE was awarded Breakthrough Therapy Designation for the company’s single-shot chikungunya vaccine candidate, VLA1553, by the U.S. Food and Drug Administration. Read more July 7, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/07/Valneva-Logo.jpeg 44 300 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-07-07 11:45:342021-07-07 12:51:05Valneva Awarded FDA Breakthrough Designation for Chikungunya Vaccine Candidate